The Ultimate Shame Of 340B ESP and Drug Manufacturer Restrictions

January 10, 2023340B, 340B ESP, Covered Entities, Drug Manufacturer Restrictions

Making the rich richer at the expense of the poorest and most vulnerable. Why was the 340B program created? Nobody’s ever put it better than the Association of American Medical Colleges (AAMC): “Congress created the 340B Drug Pricing Program in 1992 to protect safety-net hospitals from escalating drug prices by allowing them to purchase outpatient … Read More

Seven Steps For Overcoming 340B ESP and Other Manufacturer Restrictions on 340B Pricing

December 20, 2022340B, 340B ESP, Contract Pharmacy, Covered Entities, Requirements, Specialty Drugs, Specialty Pharmacy

ProxsysRx’s process for recovering lost 340B savings and revenue As we’ve noted in multiple earlier blog posts, 340B ESP is nothing short of a blatant, lawless tactic used by scores of drug manufacturers to disallow the discounts they are legally obligated to offer eligible entities. At the same time, a number of additional manufacturers are … Read More

Which TPAs Are The Best At Optimizing 340B Savings And Revenue?

December 8, 2022340B, Audit, Compliance, Contract Pharmacy, Covered Entities, TPA / TPAs

A covered entity’s guide to selecting TPAs for its 340B program TPAs play a critical role in any covered entity’s 340B program. It’s their job to match contract pharmacies’ prescription claims with patient data provided by the health systems they serve, to determine 340B eligibility — and generate entity savings. Without those matches, no prescriptions … Read More

How To Manage A Director of Pharmacy’s Responsibilities And An Optimized 340B Program. Without Hiring More Staff.

November 9, 2022340B, 340B ESP, Bedside Prescription Delivery, Compliance, Contract Pharmacy, Meds To Beds, Outpatient Tracking, Patient Eligibility, Retail / Outpatient Pharmacy, Specialty Pharmacy

Two DOPs Deal With Operations, The 340B Program, And Drug Manufacturers’ Restrictions ProxsysRx recently organized an introductory Zoom meeting between the DOPs of two health systems we serve. Southwest Mississippi Regional Medical Center’s (SMRMC) Tiffany Poole earned her Doctorate of Pharmacy degree from the University of Mississippi in 2006. A ProxsysRx pharmacist since 2018, she … Read More

What Is Your Health System’s Potential ROI With An Optimized 340B Program?

October 24, 2022340B, 340B ESP, Contract Pharmacy, Overview, Patient Eligibility, Specialty Drugs, Specialty Pharmacy

Introducing ProxsysRx’s 340B Program ROI Calculator The 340B program has often been described, and with good reason, as a black box. There are dozens of factors impacting an individual hospital’s relative success or failure in generating positive returns from a program. ProxsysRx has optimized dozens of 340B programs — generating tens of millions in savings … Read More

Specialized Software Can Only Do So Much For 340B Programs

October 6, 2022340B, 340B ESP, Compliance, Requirements

Why specialized software is essential for successful 340B programs As we’ve mentioned in several previous posts, many hospitals taking full advantage of 340B programs’ discounts save millions of dollars a year on prescription costs. However, 340B programs cover thousands of discounted drugs, and, for most eligible entities, thousands — if not tens of thousands — … Read More

Use Your Hospital’s Retail Pharmacy 340B Drug Savings To Build A Specialty Pharmacy

September 12, 2022340B, Compliance, Covered Entities, Specialty Drugs, Specialty Pharmacy

For 340B-eligible hospitals dealing with increasingly tight bottom lines (which essentially means all 340B-eligible hospitals), an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they do in traditional retail / outpatient or contract pharmacy 340B revenue. What is … Read More

Avoid These Six Common Errors When Reporting 340B-Eligible Prescriptions Through 340B ESP

August 26, 2022340B, 340B ESP, Covered Entities, Requirements

As we noted in a previous post, 340B ESP is nothing less than a brazen and (in our opinion) unlawful ploy by the drug manufacturers to evade the discounts they are legally obligated to offer eligible entities — by placing extraordinary, and unnecessary, reporting burdens on hospitals submitting claims for 340B savings. That said, until … Read More